Pediatrix Medical Group, Inc. (BMV:MD)
Mexico · Delayed Price · Currency is MXN 288.00
+8.00 (2.86%)
At close: May 13, 2025
Verve Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,941 | 2,013 | 1,995 | 1,972 | 1,911 | 1,734 | Upgrade | |
Revenue Growth (YoY) | -3.08% | 0.92% | 1.15% | 3.18% | 10.22% | -2.57% | Upgrade |
Cost of Revenue | 1,468 | 1,559 | 1,573 | 1,505 | 1,398 | 1,285 | Upgrade |
Gross Profit | 472.72 | 454.34 | 421.57 | 467.03 | 513.24 | 449.32 | Upgrade |
Selling, General & Admin | 235.99 | 238.44 | 227.54 | 231.4 | 263.36 | 248.95 | Upgrade |
Operating Expenses | 259.76 | 270.66 | 263.71 | 267.03 | 295.5 | 277.39 | Upgrade |
Operating Income | 212.95 | 183.68 | 157.85 | 200 | 217.74 | 171.93 | Upgrade |
Interest Expense | -38.12 | -40.74 | -42.08 | -39.7 | -68.72 | -110.48 | Upgrade |
Interest & Investment Income | 12.38 | 5.77 | 4.34 | 3.67 | 13.65 | 17.91 | Upgrade |
Earnings From Equity Investments | 2.27 | 2.34 | 2.06 | 1.72 | 1.91 | 1.59 | Upgrade |
EBT Excluding Unusual Items | 189.49 | 151.05 | 122.17 | 165.7 | 164.58 | 80.95 | Upgrade |
Merger & Restructuring Charges | -52.64 | -64.26 | -2.22 | -27.31 | -22.1 | -73.8 | Upgrade |
Impairment of Goodwill | 3.6 | -150.64 | -148.31 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | -20 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 1.17 | -9.7 | - | - | 7.28 | - | Upgrade |
Asset Writedown | - | -27.79 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | -57.02 | -14.53 | - | Upgrade |
Pretax Income | 141.62 | -101.34 | -48.36 | 81.37 | 135.23 | 7.15 | Upgrade |
Income Tax Expense | 31.7 | -2.27 | 12.05 | 18.81 | 27.24 | 16.73 | Upgrade |
Earnings From Continuing Operations | 109.92 | -99.07 | -60.41 | 62.56 | 107.99 | -9.58 | Upgrade |
Earnings From Discontinued Operations | - | - | - | 3.77 | 22.95 | -786.91 | Upgrade |
Net Income to Company | 109.92 | -99.07 | -60.41 | 66.33 | 130.94 | -796.49 | Upgrade |
Minority Interest in Earnings | - | - | - | 0 | 0.03 | - | Upgrade |
Net Income | 109.92 | -99.07 | -60.41 | 66.34 | 130.96 | -796.49 | Upgrade |
Net Income to Common | 109.92 | -99.07 | -60.41 | 66.34 | 130.96 | -796.49 | Upgrade |
Net Income Growth | - | - | - | -49.35% | - | - | Upgrade |
Shares Outstanding (Basic) | 84 | 83 | 82 | 83 | 85 | 83 | Upgrade |
Shares Outstanding (Diluted) | 85 | 83 | 82 | 84 | 86 | 83 | Upgrade |
Shares Change (YoY) | 2.21% | 1.37% | -2.28% | -1.99% | 2.92% | -0.73% | Upgrade |
EPS (Basic) | 1.31 | -1.19 | -0.73 | 0.79 | 1.54 | -9.55 | Upgrade |
EPS (Diluted) | 1.29 | -1.19 | -0.73 | 0.78 | 1.53 | -9.55 | Upgrade |
EPS Growth | - | - | - | -48.62% | - | - | Upgrade |
Free Cash Flow | 226.99 | 184.55 | 104 | 137.23 | 44.49 | 175.83 | Upgrade |
Free Cash Flow Per Share | 2.69 | 2.21 | 1.26 | 1.63 | 0.52 | 2.11 | Upgrade |
Gross Margin | 24.36% | 22.57% | 21.14% | 23.68% | 26.86% | 25.91% | Upgrade |
Operating Margin | 10.97% | 9.13% | 7.91% | 10.14% | 11.39% | 9.92% | Upgrade |
Profit Margin | 5.66% | -4.92% | -3.03% | 3.36% | 6.85% | -45.93% | Upgrade |
Free Cash Flow Margin | 11.70% | 9.17% | 5.21% | 6.96% | 2.33% | 10.14% | Upgrade |
EBITDA | 236.73 | 215.91 | 194.02 | 235.64 | 249.89 | 200.37 | Upgrade |
EBITDA Margin | 12.20% | 10.73% | 9.73% | 11.95% | 13.08% | 11.56% | Upgrade |
D&A For EBITDA | 23.77 | 32.23 | 36.17 | 35.64 | 32.15 | 28.44 | Upgrade |
EBIT | 212.95 | 183.68 | 157.85 | 200 | 217.74 | 171.93 | Upgrade |
EBIT Margin | 10.97% | 9.13% | 7.91% | 10.14% | 11.39% | 9.92% | Upgrade |
Effective Tax Rate | 22.39% | - | - | 23.11% | 20.14% | 234.02% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.